Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes (SUBCUE)
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Teplizumab (MGA031) in Adults With Type 1 Diabetes Mellitus
Sponsor: Eli Lilly and Company
Terminated
This trial was terminated. No reason was provided.
This PHASE1 trial investigates Type 1 Diabetes Mellitus and is currently terminated or withdrawn. Eli Lilly and Company leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Mar 2022 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- MacroGenics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.